author-photo

M Waldron-Lynch

Hoffmann-La Roche

11

Papers

168

Citations

Citation Trend

Filter By

Papers (11) Sort By

JournalConferenceOthers

P85.04 Capmatinib in Patients with METex14-Mutated Non-Small Cell Lung Cancer: GEOMETRY Mono-1 Asian Subgroup Analysis

2021 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Capmatinib in patients with METex14-mutated or high-level MET-amplified advanced non-small- cell lung cancer (NSCLC) : results from cohort 6 of the phase 2 GEOMETRY mono-1 study

2020 Onkologie
Show All
- Source
- Cite
- Save
Citations (0)
Capmatinib in patients with high-level MET-amplified advanced non-small cell lung cancer (NSCLC) : results from the phase 2 GEOMETRY mono-1 study

2020 Onkologie
Show All
- Source
- Cite
- Save
Citations (1)
Correction to: Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Abstract P5-20-04: Safety of adjuvant treatment with pertuzumab plus trastuzumab after neoadjuvant anthracycline-based chemotherapy in patients with HER2-positive localized breast cancer: Updated results from the BERENICE study

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (63)
Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer

2018 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (77)
Abstract P4-21-02: Pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: Efficacy analysis of a phase II cardiac safety study (TRYPHAENA)

2017 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
Abstract P4-21-41: Primary analysis of BERENICE: A phase II cardiac safety study of pertuzumab, trastuzumab, and neoadjuvant anthracycline-based chemotherapy in patients with locally advanced, inflammatory, or early-stage, unilateral, and invasive HER2-positive breast cancer

2017 Cancer Research
Show All
- Source
- Cite
- Save
Citations (3)
Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab

2017 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (23)

© Copyright 2015-2020 Acemap, Inc. Shanghai Jiao Tong University.

沪ICP备18028330号